HIMS Stock Jumps 8% as JPMorgan Facility and Analyst Upgrades Fuel Rally

Quick overview

Hims & Hers Health (HIMS) surged to $37.57 after adding a $400 million receivables facility and drawing fresh analyst optimism around weight-loss drugs and peptides.

Hims & Hers Rally Builds on Liquidity and Growth Optimism

Hims & Hers Health Inc. (NYSE: HIMS) jumped sharply on Wednesday, closing at $37.57 after gaining 8.36%. The move pushed the telehealth stock back into focus as investors reacted to stronger liquidity, improved sales momentum, and renewed optimism around its weight-loss and peptide strategy.

The stock slipped slightly after hours, but the regular-session move showed buyers are still willing to chase HIMS when capital structure and growth catalysts line up.

JPMorgan Facility Unlocks $400 Million in Working Capital

The first major catalyst was Hims & Hers’ new receivables facility.

The company entered into a Master Receivables Purchase Agreement that allows subsidiaries XeCare LLC and Apostrophe Pharmacy LLC to sell eligible receivables to JPMorgan Chase Bank for cash, up to a $400 million facility limit.

The agreement has an initial 364-day term and can be extended by mutual agreement. Hims also amended its revolving credit agreement to permit the receivables program and add a new permitted indebtedness basket of up to $400 million.

For investors, the message is straightforward: Hims is adding flexible liquidity without immediately relying on equity issuance. That matters for a high-growth healthcare platform still scaling aggressively across weight loss, dermatology, sexual health, mental health, and personalized care.

Analyst Upgrades Add Momentum to HIMS Stock Rally

The second catalyst came from Wall Street.

Canaccord Genuity analyst Maria Ripps maintained a Buy rating and raised her price target to $40 from $32. BofA Securities also raised its target to $36 from $25 while keeping a Neutral rating.

Canaccord pointed to improving credit-card spending trends, stronger sales momentum, and Hims’ transition toward branded weight-loss medications. The analyst also noted that Hims has become one of Novo Nordisk’s largest telehealth partners for weight-loss drugs.

This is important because Hims has been working to pivot away from reliance on compounded GLP-1 products and toward a more durable branded-medication model.

Weight Loss and International Growth Remain Key Drivers

Hims’ growth story is increasingly tied to weight management.

The company launched generic semaglutide in Canada in late May and completed its acquisition of Eucalyptus in early June, expanding its international footprint. Canaccord noted that adjusted year-over-year sales growth improved through the second quarter, rising from mid-to-high single digits in April to high-teens growth by June.

That improving trend helped revive bullish sentiment after a volatile year for telehealth and compounded-drug names.

TradingView data shows HIMS has gained more than 35% over the past month, though the stock remains down roughly 31% over the past year, showing that the broader recovery is still rebuilding.

FDA Peptide Review Is the Next Big Test

The next major catalyst arrives later this month.

The FDA’s Pharmacy Compounding Advisory Committee is scheduled to meet July 23-24 to review seven peptides, including BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon, and Emideltide.

FDA staff have recommended against allowing compounding pharmacies to manufacture some of these peptides, citing limited evidence and unresolved safety concerns. But analysts still see the review as a potential turning point if the regulatory outcome becomes more favorable.

Hims has already positioned itself for the opportunity by acquiring a California-based peptide manufacturing facility. If the FDA softens restrictions, the peptide market could become a meaningful future revenue stream. If the agency takes a stricter stance, the stock could give back some of its recent gains.

HIMS Technical Analysis: $41 Resistance Comes Into Focus

From a technical perspective, HIMS remains in a strong short-term uptrend, but the chart is becoming more sensitive to headline risk.

The stock closed at $37.57, holding above the $36 support area that traders are watching as a recent pivot level. As long as HIMS remains above $36, dip buyers are likely to keep defending the move.

The first upside level is $40, which lines up with Canaccord’s new price target and is likely to become a psychological resistance zone. Above that, $41 is the major technical resistance area where momentum could stall if volume fades.

HIMS Chart – Rally Holds Above $36, But $41 Remains the Breakout Test

Momentum indicators remain constructive after the latest surge, but the rally has become extended. The stock has moved well above key short-term trend levels cited in recent market analysis, which can support bullish continuation but also increases the risk of sharper pullbacks if the FDA catalyst disappoints.

The broader trend is still repairing. Recent technical commentary notes that the stock’s short-term averages have improved, but longer-term structure has not fully healed after earlier weakness. That means HIMS can keep rallying, but it still needs follow-through above $40-$41 to confirm a cleaner breakout.

What’s Next for Hims & Hers Stock?

The first support level is $36. Below that, traders may look for a deeper pullback toward the low-$30s if momentum fades.

On the upside, $40 is the first major target, followed by $41. A clean breakout above $41 would strengthen the bullish case and could shift attention toward fresh 2026 highs.

For now, Hims & Hers has a strong catalyst stack: better liquidity, analyst upgrades, weight-loss momentum, and peptide optionality. But with the FDA review approaching, HIMS remains a high-volatility stock where regulatory headlines may decide the next major move.

ABOUT THE AUTHOR See More

Arslan Butt

Lead Markets Analyst – Multi-Asset (FX, Commodities, Crypto)

Arslan Butt serves as the Lead Commodities and Indices Analyst, bringing a wealth of expertise to the field. With an MBA in Behavioral Finance and active progress towards a Ph.D., Arslan possesses a deep understanding of market dynamics. His professional journey includes a significant role as a senior analyst at a leading brokerage firm, complementing his extensive experience as a market analyst and day trader. Adept in educating others, Arslan has a commendable track record as an instructor and public speaker. His incisive analyses, particularly within the realms of cryptocurrency and forex markets, are showcased across esteemed financial publications such as ForexCrunch, InsideBitcoins, and EconomyWatch, solidifying his reputation in the financial community.

Exxon Mobil Stock Tests Key Support as Oil Outlook and Texas Move Take Focus

3 hs ago

Save

U.S. Job Openings Increase for Second Month in a Row

11 hs ago

Save

Nasdaq Down 0.6% on Semiconductor Worries

14 hs ago

Save